Over the past decades, there has been a great interest to further understand the molecular biology of CRC, which has allowed the development of targeted therapies that are nowadays incorporated into daily clinical practice, in parallel with the implementation of routine genetic testing, such as the detection of RAS or BRAF mutations. This evidence concerns the gene BRAF and colorectal carcinoma.